REFILE-Canada's Edesa Biotech Q1 net loss widens

Overview

• Canada biopharma firm's Q1 net loss widened to $2.2 mln, driven by higher expenses

• Operating expenses rose to $2.3 mln due to increased R&D and admin costs

Outlook

• Company anticipates recruitment for vitiligo study to begin midyear 2026

• Edesa exploring accelerated commercialization pathways for paridiprubart

• Company continuing to evaluate opportunities, such as establishing investigational sites across multiple jurisdictions

Result Drivers

• VITILIGO STUDY PREPARATION - Increased R&D expenses due to manufacturing and preparations for Phase 2 study of EB06 in vitiligo patients

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Edesa Biotech Inc is $9.00, about 804.5% above its February 12 closing price of $1.00

Press Release: ID:nGNX8QP1VK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.